John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, discusses a study exploring the molecular variances between rectal and left-sided colon cancers.
Videos
Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.
Jay D. Raman, MD, professor of Surgery and chief of the Division of Urology at Penn State Milton S. Hershey Medical Center, discusses hematuria in patients with urothelial carcinoma.
Chemotherapy for Metastatic Pancreatic Cancer
Howard L. Kaufman, MD, a surgical oncologist at Rutgers Cancer Institute of New Jersey, discusses a study which showed further durable responses to avelumab (Bavencio) in patients with merkel cell carcinoma who progressed after chemotherapy.
Long-Term Strategies in Advanced HCC
Later Line Therapeutic Decisions in Metastatic HCC
Later Line Therapeutic Decisions in Metastatic HCC
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Targeting the IL-2 Pathway to Overcome Immunotherapy Resistance in Melanoma
2
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
3
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
4
Revumenib Maintenance After Allogeneic SCT Shows Feasibility in AML
5